About consun pharmaceutical grp limited - CPHGF
Consun Pharmaceutical Group Ltd. is an investment holding company, which engages in the manufacturing and sales of pharmaceutical products. It operates through the Consun Pharmaceutical and Yulin Pharmaceutical segments. The Consun Pharmaceutical segment manufactures and sells modern Chinese medicines and medical contrast medium. The Yulin Pharmaceutical segment retails traditional Chinese medicines. The company was founded by Qian Li in 1997 and is headquartered in Guangzhou, China.
CPHGF At a Glance
Consun Pharmaceutical Group Ltd.
71 Dong Peng Avenue, Eastern Section
Guangzhou, Guangdong 510760
| Phone | 86-20-82264529 | Revenue | 365.58M | |
| Industry | Pharmaceuticals: Major | Net Income | 110.73M | |
| Sector | Health Technology | 2023 Sales Growth | 5.216% | |
| Fiscal Year-end | 12 / 2024 | Employees | 3,127 | |
| View SEC Filings |
CPHGF Valuation
| P/E Current | 6.812 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 4.363 |
| Price to Sales Ratio | 1.335 |
| Price to Book Ratio | 0.947 |
| Price to Cash Flow Ratio | 3.998 |
| Enterprise Value to EBITDA | 0.808 |
| Enterprise Value to Sales | 0.263 |
| Total Debt to Enterprise Value | 0.749 |
CPHGF Efficiency
| Revenue/Employee | 116,909.434 |
| Income Per Employee | 35,411.333 |
| Receivables Turnover | 8.365 |
| Total Asset Turnover | 0.494 |
CPHGF Liquidity
| Current Ratio | 2.862 |
| Quick Ratio | 2.616 |
| Cash Ratio | 2.397 |
CPHGF Profitability
| Gross Margin | 74.193 |
| Operating Margin | 29.592 |
| Pretax Margin | 33.346 |
| Net Margin | 30.29 |
| Return on Assets | 14.96 |
| Return on Equity | 22.979 |
| Return on Total Capital | 18.978 |
| Return on Invested Capital | 22.945 |
CPHGF Capital Structure
| Total Debt to Total Equity | 14.105 |
| Total Debt to Total Capital | 12.362 |
| Total Debt to Total Assets | 9.287 |
| Long-Term Debt to Equity | 0.107 |
| Long-Term Debt to Total Capital | 0.094 |